Summary

for people ages 12-75 (full criteria)
at San Diego, California and other locations
study started
estimated completion

Description

Summary

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy.

Official Title

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

Keywords

Atopic Dermatitis Upadacitinib ABT-494 Dermatitis, Atopic Dermatitis Eczema

Eligibility

You can join if…

Open to people ages 12-75

  • Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body surface area (BSA), and pruritus
  • Candidate for systemic therapy or have recently required systemic therapy for atopic dermatitis

You CAN'T join if...

  • Prior exposure to any Janus kinase (JAK) inhibitor
  • Unable or unwilling to discontinue current AD treatments prior to the study
  • Requirement of prohibited medications during the study
  • Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
  • Female subject who is pregnant, breastfeeding, or considering pregnancy during the study

Locations

  • UCSD Rady's Children's Hospital /ID# 208244 accepting new patients
    San Diego California 92123-4232 United States
  • University of California Irvine /ID# 205136 accepting new patients
    Irvine California 92697-1385 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03607422
Phase
Phase 3
Study Type
Interventional
Last Updated